


ZO-1 (H-300): sc-10804



The Power to Question

BACKGROUND

Tight junctions are complexes of proteins that create intercellular boundaries between the plasma membrane domains of epithelial and endothelial cells. Many of the tight junction-associated proteins are members of the membrane-associated guanylate kinase (MAGUK) family and include occludin, ZO-1, ZO-2 and ZO-3. These proteins are thought to have both structural and signaling roles, and are characteristically defined by three protein-protein interaction modules: the PDZ domain, the SH3 domain and the guanylate kinase (GuK) domain. ZO-1 forms complexes with either ZO-2 or ZO-3. In addition, these proteins can also associate with claudin, occludin and F-actin, at tight junction stands, where they provide a linkage between the actin cytoskeleton and the tight junction. ZO-1 expression is significantly reduced in many breast cancer lines. ZO-2 and ZO-3 are ubiquitously expressed within epithelial tight junctions, and unlike ZO-1, which is also expressed at cell junctions of cardiac myocytes, ZO-2 is not expressed in nonepithelial tissue.

CHROMOSOMAL LOCATION

Genetic locus: TJP1 (human) mapping to 15q13; Tjp1 (mouse) mapping to 7 C.

SOURCE

ZO-1 (H-300) is a rabbit polyclonal antibody raised against amino acids 1437-1736 of ZO-1 of human origin.

PRODUCT

Each vial contains 200 µg IgG in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin.

APPLICATIONS

ZO-1 (H-300) is recommended for detection of ZO-1 of mouse, rat and human origin by Western Blotting (starting dilution 1:200, dilution range 1:100-1:1000), immunoprecipitation [1-2 µg per 100-500 µg of total protein (1 ml of cell lysate)], immunofluorescence (starting dilution 1:50, dilution range 1:50-1:500) and solid phase ELISA (starting dilution 1:30, dilution range 1:30-1:3000).

ZO-1 (H-300) is also recommended for detection of ZO-1 in additional species, including equine, canine, bovine and porcine.

Suitable for use as control antibody for ZO-1 siRNA (h): sc-29829, ZO-1 siRNA (m): sc-29832, ZO-1 shRNA Plasmid (h): sc-29829-SH, ZO-1 shRNA Plasmid (m): sc-29832-SH, ZO-1 shRNA (h) Lentiviral Particles: sc-29829-V and ZO-1 shRNA (m) Lentiviral Particles: sc-29832-V.

Molecular Weight of ZO-1: 220 kDa.

Positive Controls: rat testis extract: sc-2400 or ZO-1 (h): 293T Lysate: sc-178194.


STORAGE

Store at 4° C, **DO NOT FREEZE**. Stable for one year from the date of shipment. Non-hazardous. No MSDS required.


RESEARCH USE

For research use only, not for use in diagnostic procedures.

DATA



ZO-1 (H-300): sc-10804. Western blot analysis of ZO-1 expression in non-transfected: sc-117752 (A) and human ZO-1 transfected: sc-178194 (B) 293T whole cell lysates.



ZO-1 (H-300): sc-10804. Western blot analysis of ZO-1 expression in non-transfected: sc-117752 (A) and human ZO-1 transfected: sc-178195 (B) 293T whole cell lysates.

SELECT PRODUCT CITATIONS

- Séguin, R., et al. 2003. Regulation and functional effects of monocyte migration across human brain-derived endothelial cells. *J. Neuropathol. Exp. Neurol.* 62: 412-419.
- Yang, Y., et al. 2006. Transforming growth factor-β1 induces epithelial-to-mesenchymal transition and apoptosis via a cell cycle-dependent mechanism. *Oncogene* 25: 7235-7244.
- Bhattacharya, R., et al. 2008. The neurotransmitter dopamine modulates vascular permeability in the endothelium. *J. Mol. Signal.* 3: 14.
- Ronaldson, P.T., et al. 2009. Transforming growth factor-β signaling alters substrate permeability and tight junction protein expression at the blood-brain barrier during inflammatory pain. *J. Cereb. Blood Flow Metab.* 29: 1084-1098.
- Omri, S., et al. 2010. The outer limiting membrane (OLM) revisited: clinical implications. *Clin. Ophthalmol.* 4: 183-195.
- Chen, C.H., et al. 2010. Hydrogen gas reduced acute hyperglycemia-enhanced hemorrhagic transformation in a focal ischemia rat model. *Neuroscience* 169: 402-414.
- Li, Q.Q., et al. 2011. Involvement of NFκB/miR-448 regulatory feedback loop in chemotherapy-induced epithelial-mesenchymal transition of breast cancer cells. *Cell Death Differ.* 18: 16-25.
- Awsare, N., et al. 2011. Claudin-11 decreases the invasiveness of bladder cancer cells. *Oncol. Rep.* 25: 1503-1509.

MONOS
Satisfaction
Guaranteed

Try **ZO-1 (R40.76): sc-33725**, our highly recommended monoclonal alternative to ZO-1 (H-300). Also, for AC, HRP, FITC, PE, Alexa Fluor® 488 and Alexa Fluor® 647 conjugates, see **ZO-1 (R40.76): sc-33725**.